EP PerMed Newsletter 17 | 23 February 2026

EP PerMed NSC2025 funded Networks

CHALLENGE4PRE

Building a "Think Tank" for personalised PREdiction, PREvention and treatment of PREeclampsia and hypertension in PREgnancy as a window for future maternal and fetal cardiometabolic health

Pregnancy is a stress test that can reveal later-life health risks for mother and child. Preeclampsia is an early warning sign for cardiometabolic diseases, but many at risk are not identified in time. The aim of this networking event is to improve early prediction and prevention of pregnancy complications and related long-term diseases. The event is going to be organised in October 2026 in Budapest (Hungary) and will engage a broad spectrum of translational stakeholders critical to achieving this objectives, including scientific and clinical experts.

Read more

Allergy4PM

From Research to Implementation of Personalised Medicine in Allergy

Allergic conditions such as asthma, allergic rhinitis, and food allergies affect millions of people in Europe. Especially individuals with severe symptoms experience major limitations in their daily lives. In this project, two previously funded ERA PerMed consortia, PERMEABLE and POC4Allergies, will collaborate to promote personalised allergy care. By joining forces and organising a joint networking event, they aim to identify existing barriers and work towards narrowing the gap between scientific research and routine allergy care.

Read more

E-SCOPE

Europe for Solutions: Collaborative network to Overcome Legal, Ethical, and Social barriers in PErsonalized Medicine

E-SCOPE brings together key stakeholders in personalised medicine to strengthen the translation of Ethical, Legal and Social Issues (ELSI) research into clinical practice, building on the strong foundations of ELSI work packages from ERAPerMed projects. E-SCOPE will convene a 3 days hybrid Stakeholder Consensus Conference, a methodology connecting clinicians, PM researchers, ethics committee members, patient representatives and organisations, and technology developers.

Read more

PRISM

Digital Twins for Personalised Radiotherapy through Integrated Simulation and Modelling

The PRISM networking event aims to bring together a transnational and interdisciplinary community to address key translational challenges in Personalised Medicine, with a specific focus on the role of subject specific Digital Twins (DTs) in advancing personalised radiotherapy. The event will serve as a platform to consolidate lessons learned, harmonise methodological approaches, and define future directions for translational research on DTs in oncology.

Read more

IMPACT-T

Implementing Personalised Medicine Approaches into Clinical Trials for T-Cell Malignancies

T-cell leukemias and lymphomas are rare blood cancers that are difficult to treat and often have poor outcomes. One promising way to improve care is personalised medicine, which aims to match treatments to the unique biological features of each patient and their cancer. The IMPACT-T networking event aims to overcome these challenges by bringing together researchers, doctors, patient organisations, policymakers and industry partners from across Europe. Participants will share knowledge and lessons learned from previous EU-funded research projects and work together to identify gaps that are slowing progress.

Read more

PIONEER

Personalised Medicine in Ovarian Cancer Evolution and Treatment Response

High-grade serous carcinoma (HGSC) is the most common and lethal form of ovarian cancer. While many patients initially respond to chemotherapy, relapse is almost inevitable. Improving outcomes requires a deeper understanding of tumour evolution over time and the impact of treatment on both cancer cells and their microenvironment. The PIONEER networking event will unite clinicians, researchers, data scientists, industry, patient representatives and policy experts to address this challenge.

Read more

MetaNet

Translating Omics Discoveries into Personalised Prevention and Care for Metabolic Disorders

Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) are major global health challenges with high morbimortality. The EP PerMed projects UNMASK and OPTIMA aim to improve understanding of the molecular mechanisms of these diseases using omics-based approaches to support personalised prevention and innovative strategies in African and European populations. This hybrid networking event, organised in Seville (Spain) and online, will gather researchers, clinicians, omics experts, patient representatives and policymakers to accelerate the transfer of EP PerMed results into healthcare solutions.

Read more

re-BOOT

Rewire Oncogenic Chromatin in Mature B-Cell Cancers via targeting the BOB1-OCT2-driven Super-Enhancer Landscape

The re-BOOT consortium is a transnational, interdisciplinary initiative dedicated to overcoming drug resistance in aggressive B-cell cancers. Building upon the research foundations of the BATMAN and HiRisk-HiGain projects (funded by ERA PerMed and EP PerMed), the consortium focuses on a specific "master switch" that allows cancer cells to evade treatment: the BOB1-OCT2 complex.

Read more

AML-TransNet

Designing Personalised Medicine in Acute Myeloid Leukemia

Acute myeloid leukaemia (AML) is an aggressive blood cancer that looks different from one patient to the next and the disease even changes over time within the same patient. Two previously funded ERA PerMed and EP PerMed projects have developed cutting-edge ways to “read” what AML cells are doing, based on their cellular signals, protein they express and their energy use. This networking meeting will bring together physicians, researchers, data and AI scientists, biobank specialists, and patient representatives to turn those advances into practical tools for patient care.

Read more

VOICE PM

Advancing Cancer Patient Voice in Personalised Medicine Research

While personalised medicine offers groundbreaking diagnostic and therapeutic potential, its successful integration into healthcare requires the early, continuous inclusion of patient perspectives. The Voice PM project aims to organise a networking event which addresses the vital need for meaningful patient involvement in translational research for personalised medicine.

Read more

HEPMED

Health economics supporting the implementation of personalised medicine in healthcare

This networking event will focus on the main challenges of putting personalised medicine (PM) into everyday healthcare. These include difficulties with real-world implementation, limited experience with health economic (HE) modelling in genomics, and the ongoing need for better collaboration across countries and sectors. The expected outcomes include shared input to support the development of HE models for genomics, practical steps to help integrate PM into healthcare systems, and the creation of a lasting network to support continued collaboration after the event.

Read more

BIPOLAR-CAN

Personalised Medicine in Bipolar Disorders: Building a Collaborative Action Network

Bipolar disorder affects millions of people across Europe. It causes strong shifts in mood, energy, and behaviour that can disrupt daily life and put pressure on families and health services. Many current treatments do not work well for everyone because they do not consider personal differences in biology, lifestyle, and environment. The BIPOLAR-CAN networking event aims to address this gap by bringing together experts from two ERA PerMed projects along with doctors, policymakers, patient groups, and industry partners. Their goal is to help turn scientific discoveries into practical improvements in everyday care.

Read more

DECODE-GBM-Med

Synergies to decode Glioma Biology for Personalised Glioma Medicine

The primary objective of DECODE-GBM-Med is to create a strategic networking event that will establish a forum for leveraging our strengths to decode the complex biology of glioma, understand the underlying mechanisms, and stratify patients to advance personalised glioma medicine. As a result, basic researchers will elucidate the mechanisms of GBM biology, multi-omics experts will decode the readouts and biomarkers, chemical biologists will identify the targets, clinicians will assess the relevance of the findings and their applicability in the clinical setting, and stakeholders will take steps to facilitate market research and implementation.

Read more

See all projects